An_open_label_study_of_oral_transmucosal_fentanyl_citrate_(OTFC)_for_the_treatment_of_breakthrough_cancer_pain._Ten_patients_with_advanced_cancer_and_breakthrough_pain_between_the_ages_of_39_and_78_received_oral_transmucosal_fentanyl_citrate_(10-15_micrograms/kg)_4_or_5_times_each_over_2_days_(42_total_administrations)_in_an_open_study._Baseline_vital_sign_and_rating_scale_results_did_not_vary_over_administrations,_except_for_heart_rate_which_showed_an_8_beats/min_decrease_over_4_administrations._Heart_rate_and_oxygen_saturation_did_not_vary_significantly_over_120_min_of_evaluation,_and_minimal_changes_in_blood_pressure_and_respiration_rate_were_found._Significant_reduction_in_pain_scores_as_measured_by_a_pain_descriptive_scale,_the_McGill-Melzack_scale,_and_a_numeric_(VAS)_scale_were_seen_at_all_evaluations_from_5_to_120_min._Average_time_to_onset_of_pain_relief_was_9.5_min_after_administration._Wellbeing_was_significantly_increased_at_all_evaluations._Activity_level_as_recorded_by_the_investigator_was_significantly_reduced_from_10_to_30_min_after_administration,_however,_activity_level_as_reported_by_the_patient_was_significantly_increased_at_5_min_and_from_60_to_120_min_after_OTFC_administration._There_were_no_significant_adverse_effects.